Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids and Organs-on-Chips 2021

Evan Cromwell's Biography

Evan Cromwell, President & CEO, Protein Fluidics

Dr. Cromwell is a successful entrepreneur and an innovative leader of instrument and assay product development teams. He has 30 years of senior executive and technical experience in research, engineering, bioassay development, production, and marketing. Prior to founding Protein Fluidics, he served as Director of Research at Molecular Devices and was a leader of a cross-OpCo scientific team for the Danaher Life Sciences group. He was Founder and President of Blueshift Biotechnologies, a high-content screening and analysis venture that was acquired by Molecular Devices in 2008. His passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities. He holds a B.S. in Chemistry from Caltech and earned his Ph.D. in Physical Chemistry at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 16 patents.

Evan Cromwell Image

Automated 3D Cell-Based Assays Using a Novel Flowchip System

Monday, 22 March 2021 at 12:30

Add to Calendar ▼2021-03-22 12:30:002021-03-22 13:30:00Europe/LondonAutomated 3D Cell-Based Assays Using a Novel Flowchip System3D-Culture, Organoids and Organs-on-Chips 2021 in

There is an increasing interest in using three-dimensional (3D) cell structures for modeling tumors, organs, and tissue to accelerate translation research. Significant progress has been made in formation of such structures to recapitulate the in vivo environment but performing complex assays with them can be challenging.  Organoids can be subject to loss or damage from pipettes during common steps such as media exchange, supernatant sampling, or immunofluorescence staining.  We present here results from automated organoid assays using a PuĀ·MA System for research in oncology therapeutics, single organoid secretion, and metabolite sampling.  The system uses a novel flowchip that contains organoid samples connected to multiple reservoirs via microfluidic channels.  Assay reagents are transferred in and out of the sample well without loss of or damage to the organoids.  The bottom of the sample chamber is thin optically clear plastic compatible with high resolution fluorescence imaging.  The whole system can be kept in an incubator allowing long term cellular assays to be performed.  In a first example, effects of anti-cancer drugs on cancer spheroids were assayed using high content imaging.  Confocal imaging allowed 3D resolution of spheroid structures and complex analysis of cytotoxic effects.  In addition, conditioned media was removed and analyzed for VEGF.  In a second example, triple negative breast cancer (TNBC) patient-derived organoids were used for disease modeling.  This novel assay system using microfluidics enables automation of 3D cell-based cultures that mimic in vivo conditions, performs multi-dosing protocols and multiple media exchanges, provides gentle and convenient handling of spheroids and organoids, and allows a wide range of assay detection modalities.

Add to Calendar ▼2021-03-22 00:00:002021-03-23 00:00:00Europe/London3D-Culture, Organoids and Organs-on-Chips 20213D-Culture, Organoids and Organs-on-Chips 2021 in